NASDAQ:INM InMed Pharmaceuticals (INM) Stock Price, News & Analysis $2.06 -0.58 (-21.97%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$2.20 +0.14 (+6.60%) As of 03/28/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InMed Pharmaceuticals Stock (NASDAQ:INM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InMed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.06▼$2.6650-Day Range$2.06▼$5.0552-Week Range$2.06▼$15.70Volume37,830 shsAverage Volume228,725 shsMarket Capitalization$2.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Read More… Remove Ads InMed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreINM MarketRank™: InMed Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for InMed Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of InMed Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InMed Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInMed Pharmaceuticals has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about InMed Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.05% of the float of InMed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently decreased by 19.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInMed Pharmaceuticals does not currently pay a dividend.Dividend GrowthInMed Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.05% of the float of InMed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverInMed Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InMed Pharmaceuticals has recently decreased by 19.33%, indicating that investor sentiment is improving significantly. News and Social Media4.1 / 5News Sentiment1.43 News SentimentInMed Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for InMed Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest1 people have searched for INM on MarketBeat in the last 30 days. MarketBeat Follows1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.85% of the stock of InMed Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 20.12% of the stock of InMed Pharmaceuticals is held by institutions.Read more about InMed Pharmaceuticals' insider trading history. Receive INM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address INM Stock News HeadlinesInMed Pharmaceuticals Board Reshuffle After Director ResignationFebruary 14, 2025 | tipranks.comInMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024)February 14, 2025 | finance.yahoo.comTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 30, 2025 | Porter & Company (Ad)InMed Pharmaceuticals: InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular DegenerationFebruary 3, 2025 | finanznachrichten.deInMed advances AMD treatment with promising IVT drug formulationFebruary 3, 2025 | msn.comInMed Pharmaceuticals announces INM-089 IVT formulation as drug candidateFebruary 3, 2025 | markets.businessinsider.comInMed Advances INM-089 for Dry AMD Treatment with New Intravitreal FormulationFebruary 3, 2025 | tipranks.comInMed announces ‘positive’ results from in vivo preclinical Alzheimer’s studyJanuary 22, 2025 | markets.businessinsider.comSee More Headlines INM Stock Analysis - Frequently Asked Questions How have INM shares performed this year? InMed Pharmaceuticals' stock was trading at $4.74 on January 1st, 2025. Since then, INM stock has decreased by 56.5% and is now trading at $2.06. View the best growth stocks for 2025 here. How were InMed Pharmaceuticals' earnings last quarter? InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its earnings results on Wednesday, February, 12th. The company reported ($3.64) earnings per share (EPS) for the quarter. InMed Pharmaceuticals had a negative net margin of 163.75% and a negative trailing twelve-month return on equity of 90.74%. When did InMed Pharmaceuticals' stock split? InMed Pharmaceuticals's stock reverse split before market open on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are InMed Pharmaceuticals' major shareholders? InMed Pharmaceuticals' top institutional shareholders include AdvisorShares Investments LLC (5.34%). Insiders that own company stock include Eric A Adams and Andrew Hull. View institutional ownership trends. How do I buy shares of InMed Pharmaceuticals? Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL). Company Calendar Last Earnings2/12/2025Today3/30/2025Next Earnings (Estimated)5/12/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INM CIK1728328 Webwww.inmedpharma.com Phone604-669-7207FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,680,000.00 Net Margins-163.75% Pretax Margin-163.58% Return on Equity-90.74% Return on Assets-71.70% Debt Debt-to-Equity Ratio0.09 Current Ratio3.05 Quick Ratio2.44 Sales & Book Value Annual Sales$4.83 million Price / Sales0.51 Cash FlowN/A Price / Cash FlowN/A Book Value$5.12 per share Price / Book0.40Miscellaneous Outstanding Shares1,207,000Free Float711,000Market Cap$2.49 million OptionableNot Optionable Beta0.18 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:INM) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.